Vimarsana
Biggest News Aggregation in the World

Page 4 - Cohort Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cohort Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cohort Study Today - Breaking & Trending Today

The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study - Vimarsana News

The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study

In this modelling study, Keri N Althoff and colleagues employ an agent-based simulation model to forecast the burden of comorbidity and multimorbidity in individuals who have initiated ART in the US.

Source: plos.org
Antidepressant Exposure In Utero May Negatively Impact Motor Skills in 2-Year-Old Children - Vimarsana News

Antidepressant Exposure In Utero May Negatively Impact Motor Skills in 2-Year-Old Children

A new study in Frontiers of Pharmacology finds that antidepressant use during pregnancy is linked to reduced motor skills in children at 2 years old. The Study finds antidepressant use during pregnancy may impact motor skills of child

Blood Type and Health - Vimarsana News

Blood Type and Health

Does your blood type play a role in your risk for disease? Find out how it fares in the face of certain conditions.

Source: webmd.com
Qatar Biobank makes significant contribution to local health research - Vimarsana News

Qatar Biobank makes significant contribution to local health research

Doha, Qatar:Qatar Biobank, a member of Qatar Foundation (QF), has achieved significant milestones in the 2022 2023 period, demonstrating its unwaverin...

Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition - Vimarsana News

Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition

BOSTON--(BUSINESS WIRE)--Dec 11, 2023--